Literature DB >> 9101149

Antibiotic prophylaxis in gastrointestinal endoscopy: a report by a Working Party for the British Society of Gastroenterology Endoscopy Committee.

V Mani1, K Cartwright, J Dooley, E Swarbrick, P Fairclough, C Oakley.   

Abstract

Antibiotic prophylaxis is recommended for endoscopic procedures if the patient is at high risk of endocarditis or of symptomatic bacteraemia as a consequence of immunosuppression or neutropenia. In most circumstances parenteral amoxycillin and gentamicin are recommended. The addition of parenteral metronidazole is recommended in patients with neutropenia. Vancomycin or teicoplanin are recommended in patients allergic to penicillin. Antibiotic prophylaxis is recommended for all patients undergoing ERCP with evidence of biliary stasis or pancreatic pseudocyst. Oral ciprofloxacin or parenteral gentamicin (or parenteral quinolone, cephalosporin or ureidopenicillin) are recommended for ERCP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101149     DOI: 10.1055/s-2007-1004085

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  4 in total

1.  CT colonography and transient bacteraemia: implications for antibiotic prophylaxis.

Authors:  C A Ridge; M R Carter; L P Browne; R Ryan; C Hegarty; K Schaffer; D E Malone
Journal:  Eur Radiol       Date:  2010-08-15       Impact factor: 5.315

2.  Intestinal obstruction associated with chronic peritonitis caused by Sphingomonas paucimobilis.

Authors:  Alberto Di Leo; Rosanna Busetti; Teresa Pusiol; Francesco Piscioli; Ilaria Franceschetti; Francesco Ricci
Journal:  Clin J Gastroenterol       Date:  2009-02-27

Review 3.  Two case reports of gastroendoscopy-associated Acinetobacter baumannii bacteremia.

Authors:  Chang-Hua Chen; Shun-Sheng Wu; Chieh-Chen Huang
Journal:  World J Gastroenterol       Date:  2013-05-14       Impact factor: 5.742

4.  Post-ERCP infection and its epidemiological and clinical characteristics in a large Chinese tertiary hospital: a 4-year surveillance study.

Authors:  Mingmei Du; Jijiang Suo; Bowei Liu; Yubin Xing; Liangan Chen; Yunxi Liu
Journal:  Antimicrob Resist Infect Control       Date:  2017-12-29       Impact factor: 4.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.